Kummeth Charles R. Form 4 BIO-TECHNE / Charles R. Kummeth ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Kummeth Charles R.

(Last)

(First)

(Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS

55413

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/17/2021		S⁽¹⁾		6,732	D	$449.35⁽²⁾	160,172⁽³⁾	D
Common Stock	06/17/2021		S⁽¹⁾		1,698	D	$450.39⁽⁴⁾	158,474⁽³⁾	D
Common Stock	06/17/2021		S⁽¹⁾		1,050	D	$451.54⁽⁵⁾	157,424⁽³⁾	D
Common Stock	06/17/2021		S⁽¹⁾		109	D	$452.13	157,315⁽³⁾	D
Common Stock	06/18/2021		S⁽¹⁾		2,583	D	$449.09⁽⁶⁾	154,732⁽³⁾	D
Common Stock	06/18/2021		S⁽¹⁾		326	D	$450.37⁽⁷⁾	154,406⁽³⁾	D
Common Stock								100	I	By Step-Son
Common Stock								100	I	By Step-Daughter

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$108.49							⁽⁸⁾	08/07/2022	Common Stock	95,346		95,346	D
Stock Options (Right to Buy)	$108.49							⁽⁸⁾	08/07/2022	Common Stock	79,517		79,517	D
Stock Options (Right to Buy)	$106.59							⁽⁸⁾	08/18/2023	Common Stock	154,169		154,169	D
Stock Options (Right to Buy)	$106.59							⁽⁸⁾	08/18/2023	Common Stock	102,779		102,779	D
Stock Options (Right to Buy)	$125.05							⁽⁸⁾	08/09/2024	Common Stock	117,342		117,342	D
Stock Options (Right to Buy)	$125.05							⁽¹⁰⁾	08/09/2024	Common Stock	78,228		78,228	D
Restricted Stock Units	⁽⁹⁾							⁽¹¹⁾	⁽¹¹⁾	Common Stock	16,918		16,918	D
Stock Options (Right to Buy)	$177.32							⁽¹¹⁾	08/08/2025	Common Stock	90,334		90,334	D
Stock Options (Right to Buy)	$177.32							⁽¹²⁾	08/08/2025	Common Stock	60,222		60,222	D
Restricted Stock Units	⁽⁹⁾							⁽¹³⁾	⁽¹³⁾	Common Stock	16,937		16,937	D
Stock Options (Right to Buy)	$190.41							⁽¹³⁾	08/07/2026	Common Stock	85,725		85,725	D
Stock Options (Right to Buy)	$190.41							⁽¹⁴⁾	08/07/2026	Common Stock	57,150		57,150	D
Restricted Stock Units	⁽⁹⁾							⁽¹⁵⁾	⁽¹⁵⁾	Common Stock	12,879		12,879	D
Stock Options (Right to Buy)	$267.87							⁽¹⁵⁾	08/05/2027	Common Stock	57,442		57,442	D
Stock Options (Right to Buy)	$267.87							⁽¹⁶⁾	08/05/2027	Common Stock	38,295		38,295	D
Stock Options (Right to Buy)	$267.87							⁽¹⁷⁾	08/05/2027	Common Stock	16,650		16,650	D
Stock Options (Right to Buy)	$267.87							⁽¹⁸⁾	08/05/2027	Common Stock	16,650		16,650	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $449.00 to $449.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $450.075 to $450.95, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $451.02 to $452.02, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $449.00 to $449.63, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $450.37 to $450.625, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. Fully exercisable.

9. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

10. Options to purchase 19,557 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021.

11. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

12. Options to purchase 15,056 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 15,055 shares vest on each of 8/8/2021 and 8/8/2022.

13. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

14. Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023.

15. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

16. Options to purchase 9,573 shares vest on 8/5/21 and options to purchase 9,574 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.

17. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.

18. Options to purchase 5,550 shares vest on each of 8/5/21, 8/5/22 and 8/5/23.

Remarks:

	/s/ Brenda S. Furlow as Attorney-in-Fact for Charles R. Kummeth pursuant to Power of Attorney previously filed.	06/21/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Kummeth Charles R. Form 4BIO-TECHNE / Charles R. Kummeth ownership change